Al­ny­lam sets up 3rd po­ten­tial RNAi ap­proval with a show­case of pos­i­tive lumasir­an da­ta

A week af­ter nab­bing a pri­or­i­ty re­view, Al­ny­lam has re­leased piv­otal da­ta for their lat­est late-stage ex­per­i­men­tal drug — set­ting the stage for the RNA-tar­get­ing biotech to po­ten­tial­ly win their 3rd FDA ap­proval in as many years.

In the 39-per­son tri­al, pa­tients with an ul­tra-rare liv­er con­di­tion PH1 (pri­ma­ry hy­per­ox­aluria type 1) were giv­en ei­ther place­bo or the Al­ny­lam drug lumasir­an. Pa­tients with PH1 over­pro­duce a nat­ur­al meta­bol­ic end-prod­uct, uri­nary ox­alate, po­ten­tial­ly lead­ing to kid­ney stones and in many cas­es kid­ney fail­ure at a young age, along with dam­age across the body.

Of the 25 pa­tients who re­ceived lumasir­an, 21 — or 84% — saw their ox­alate lev­els fall to near the nor­mal range, and just over half saw their num­bers fall in­side the nor­mal range. That com­pared to 0% in the place­bo group. Over­all, pa­tients on the treat­ment arm saw their lev­els fall 65.4% on av­er­age – a 53.5% re­duc­tion when com­pared to place­bo.

Jaap Groothoff

“Un­til now we had no good ther­a­py for this dis­ease,” lead in­ves­ti­ga­tor Jaap Groothoff, who heads pe­di­atric Nephrol­o­gy at the Em­ma Chil­dren’s Hos­pi­tal in Am­s­ter­dam told End­points News. “This is the first drug that re­al­ly showed to de­crease ox­alate pro­duc­tion in these pa­tients to a lev­el we think might very ef­fec­tive and might pre­vent them from hav­ing kid­ney fail­ure.”

Like Al­ny­lam’s oth­er drugs, lumasir­an us­es RNA in­ter­fer­ence (RNAi), a tech­nique for si­lenc­ing genes by de­liv­er­ing a match­ing se­quence. Specif­i­cal­ly, lumasir­an si­lences the gene for an en­zyme used in the pro­duc­tion of ox­alate, called gly­co­late ox­i­dase. The biotech’s RNAi ri­val-turned-part­ner Dicer­na is al­so work­ing on a drug for the con­di­tion, tar­get­ing a dif­fer­ent en­zyme, called LDH, in the pro­duc­tion process.

Un­like lumasir­an, their drug is be­ing de­signed to work for all three types of pri­ma­ry hy­per­ox­aluria, al­though Al­ny­lam ex­ec­u­tives are con­fi­dent they have the bet­ter med­i­cine, cit­ing safe­ty con­cerns about the Dicer­na drug. They are al­so sev­er­al months ahead, with Dicer­na yet to re­lease piv­otal re­sults or sub­mit an NDA.

“LDH de­fi­cien­cy can lead to a buildup of lac­tate in the body and we don’t know the safe­ty con­se­quences of that,” Al­ny­lam R&D chief Ak­shay Vaish­naw told End­points.  “Of course we hope there are no safe­ty con­se­quences, but that case has to be proven as they ac­cu­mu­late more da­ta.”

Ak­shay Vaish­naw

Ques­tions still re­main for Al­ny­lam’s drug as well. In agree­ment with the FDA and EMA, Al­ny­lam test­ed changes in a bi­o­log­i­cal un­der­pin­ning for the dis­ease, rather than a symp­tom. Groothoff said the drug should al­low pa­tients to re­duce their flu­id in­take — which can be up to 6 liters per day to re­duce symp­toms — but fol­low-up tri­als will ex­am­ine whether lumasir­an can re­duce kid­ney stones or, more cru­cial­ly, whether the drug’s ef­fects will be durable and if it can fore­stall kid­ney dam­age. “We hope that it will lead to a low­er num­ber of pa­tients in kid­ney fail­ure,” Groothoff said. “There’s no rea­son to be­lieve that [the drug] would wean off af­ter some time, but we have to see.”

For Al­ny­lam, the lat­est drug is part of the cul­mi­na­tion of a strat­e­gy they turned to at the be­gin­ning of the pre­vi­ous decade, Vaish­naw said. That’s when, af­ter 10 years of re­search, they fig­ured out ways to get their RNAi se­quences in­to cells. That was eas­i­est to do in the liv­er – a nat­ur­al first tar­get, be­cause it fil­ters all sub­stances in the blood – and they fo­cused on de­vel­op­ing drugs for rare, well-de­fined ge­net­ic dis­eases found there.

That led to the ap­proval of the first RNAi drug, On­pat­tro, in 2018, for a form of amy­loi­do­sis and to the sec­ond, Givlaari, in 2019, for acute he­pat­ic poryphia. Both drugs al­so came with price tags around $500,000, al­though they could be low­ered based on how ef­fec­tive they were or how many pa­tients ul­ti­mate­ly had the rare dis­ease. Vaish­naw de­clined to com­ment on po­ten­tial pric­ing for the lumasir­an, but not­ed PH1 pa­tients could go through mul­ti­ple or­gan trans­plants and life on im­mune-sup­pres­sive drugs or dial­y­sis.

“These are tremen­dous bur­dens to these pa­tients,” he said. “This is what we’re try­ing to al­le­vi­ate, and I think that is re­turn­ing a lot of val­ue.”

Lumasir­an, though, may be the last drug in that ear­ly strat­e­gy. Al­though there are oth­er rare liv­er dis­ease can­di­dates in the pipeline, Al­ny­lam is near­ing the reg­u­la­to­ry stage for drugs that tar­get oth­er parts of the body and could have a larg­er im­pact. Al­though both drugs still go af­ter tar­gets in the liv­er, in­clisir­an – the cho­les­terol drug co-de­vel­oped by Al­ny­lam and re­cent­ly sub­mit­ted to the FDA by No­var­tis – and a Sanofi-part­nered drug for he­mo­phil­ia drug are both near­ing mar­ket.

The com­pa­ny is al­so work­ing on a Covid-19 can­di­date with Vir Biotech­nol­o­gy that di­rect­ly de­liv­ers RNAi as an in­halant di­rect­ly to the lungs. It is set to en­ter the clin­ic at the end of the year. And fur­ther out, Vaish­naw said, the com­pa­ny has fig­ured out ways of at­tach­ing mol­e­cules called lig­ands to RNA as hom­ing mis­siles, al­low­ing it to be de­liv­ered in the ner­vous sys­tem and else­where.  The com­pa­ny last year signed an $800 mil­lion-deal with Re­gen­eron for cen­tral ner­vous sys­tem dis­or­ders, in­clud­ing Alzheimer’s. They al­so have a pre­clin­i­cal NASH pro­gram and a Phase I he­pati­tis B drug.

“There’s a lot of work to do over the next 10 years,” Vaish­naw said.

Biogen CEO Michel Vounatsos (via Getty Images)

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug aducanumab hanging perilously close to disaster, Biogen is rolling the dice on a $3.1 billion deal that brings in commercial rights to one of the other spotlight neuro drugs in late-stage development — after it already failed its first Phase III.

The big biotech has turned to Sage Therapeutics for its latest deal, close to a year after the crushing failure of Sage-217, now dubbed zuranolone, in the MOUNTAIN study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Bahija Jallal (file photo)

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

Bahija Jallal’s crew at TCR pioneer Immunocore says they have nailed down a promising set of pivotal data for their lead drug in a frontline setting for a solid tumor. And they are framing this early interim readout as the convincing snapshot they need to prove that their platform can deliver on a string of breakthrough therapies now in the clinic or planned for it.

In advance of the Monday announcement, Jallal and R&D chief David Berman took some time to walk me through the first round of Phase III data for their lead TCR designed to treat rare, frontline cases of metastatic uveal melanoma that come with a grim set of survival expectations.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

In mid-August, as Kodak’s $765 million government-backed push into drug manufacturing slowly fell apart in national headlines, Ginkgo Bioworks CEO Jason Kelly got a message from his company’s government liaison: HHS wanted to know if they, too, might want a loan.

The government’s decision to lend Kodak three quarters of a billion dollars raised eyebrows because Kodak had never made drugs before. But Ginkgo, while not a manufacturing company, had spent the last decade refining new ways to produce materials inside cells and building automated facilities across Boston.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

Vivek Ramaswamy (Jeff Rumans/JPM 2020)

Urovan­t's lead drug dis­ap­points in mid-stage study as first big FDA de­ci­sion looms

Just as Urovant gets ready for its first big FDA decision on vibegron, the drug has flopped in what would’ve been a follow-on indication.

In a Phase IIa trial involving women with abdominal pain due to irritable bowel syndrome, vibegron failed to meet the bar on improving “average worst abdominal pain” over 12 weeks, compared to placebo, among IBS-D patients.

There were actually slightly more responders in the placebo group than in the drug arm, with only 40.9% of those randomized to vigebron achieving at least a 30% decrease in “worst abdominal pain” in the past 24 hours. The trial enrolled 222 women but only 189 completed the study.

Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

Genmab $GMAB has opted to ax one of its antibody-drug conjugates after watching it flop in the clinic.

The Danish biotech reported Tuesday that it decided to kill their program for enapotamab vedotin after the data gathered from expansion cohorts failed to measure up. According to the company:

While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers. Accordingly, the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

Novartis is always one of the industry’s biggest R&D spenders. As they often do toward the end of each year, company execs are highlighting the drugs they expect will most likely be winners in 2021.

And they’re also dreaming about some potential big-time lottery tickets.

As part of its annual investor presentation Tuesday, where the company allows investors and analysts to virtually schmooze with the bigwigs, Novartis CEO Vas Narasimhan will outline what he thinks are the pharma’s “Wild Cards.” The slate of five experimental drugs are those that Novartis hopes can be high-risk, high-reward entrants into the market over the next half-decade or so, and cover a wide range of indications.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.